Lanean...
Immunotherapies targeting CD38 in Multiple Myeloma
Recently, the monoclonal antibody daratumumab was approved as a single agent for the treatment of patients with relapsed/refractory Multiple Myeloma (MM). Daratumumab is an antibody targeting surface molecule CD38 on myeloma cells and the agent is already widely being used based on its good tolerabi...
Gorde:
| Argitaratua izan da: | Oncoimmunology |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5139636/ https://ncbi.nlm.nih.gov/pubmed/27999737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1217374 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|